Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis

Pharmacokinetic (PK) and pharmacodynamic (PD) analyses were conducted to determine the cumulative fraction of response (CFR) for 100 mg twice-daily (BID) and 200 mg once-daily (QD) delamanid in patients with multidrug-resistant tuberculosis (MDR-TB), using a pharmacodynamic target (PDT) that achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallikaarjun, Suresh, Chapagain, Moti L., Sasaki, Tomohiro, Hariguchi, Norimitsu, Deshpande, Devyani, Srivastava, Shashikant, Berg, Alexander, Hirota, Kuniko, Inoue, Yusuke, Matsumoto, Makoto, Hafkin, Jeffrey, Geiter, Lawrence, Wang, Xiaofeng, Gumbo, Tawanda, Liu, Yongge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927872/
https://www.ncbi.nlm.nih.gov/pubmed/33106263
http://dx.doi.org/10.1128/AAC.01207-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927872/
https://www.ncbi.nlm.nih.gov/pubmed/33106263
http://dx.doi.org/10.1128/AAC.01207-20

Ejemplares similares